EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and immunogenicity of an adjuvanted human onchocerciasis vaccine candidate, Ov MANE1 : preclinical evaluation in a mice model

Derrick Neba Nebangwa iD, Mary Teke Efeti iD, Sonia M E Momnougui, Cabirou Mounchili Shintouo, Robert Adamu Shey iD, Rene Bilingwe Ayiseh, Fidele Ntie-Kang, Stephen Mbigha Ghogomu iD

Clinical & Translational Immunology · 2026-07 · 15 (7)

DOI: 10.1002/cti2.70114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 30.06.2026. Verfasst von Derrick Neba Nebangwa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Faculty of Science University of Buea Buea Cameroon. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Onchocerciasis, caused by the filarial worm Onchocerca volvulus , remains a major public health challenge because of the limitations of ivermectin‐based control strategies, thereby highlighting the need for more innovative tools such as vaccines.

Methods

This study investigated the safety and immunogenicity of a novel multi‐epitope chimeric antigen, Ov MANE1 formulated with Freund's adjuvant, in BALB/c mice. Mice were immunised at three time points of 2‐week intervals, with blood collected at each point to measure antibody levels and immune cells.

Results

Adjuvanted‐ Ov MANE1 exhibited a promising safety profile, revealing neither any physical signs of toxicity nor behavioural abnormalities. Immunological assays showed significant increases in total IgG absorbance (OD 450 nm) after the first ( P = 0.0260) and final booster doses ( P = 0.026). Total IgG ( P = 0.0086) and IgG1 ( P = 0.0465) absorbances also increased significantly over the study period, suggesting sustained humoral immunity. Moreover, cellular responses were significantly enhanced, with elevated leucocyte count ( P = 0.0190) and increased lymphocyte activity ( P = 0.0397) observed in the adjuvanted‐ Ov MANE1 group compared to the control. Indeed, total leucocytes increased progressively from Day 0 to Day 39, with significant differences recorded in the test group between doses: Days 0–14 ( P = 0.0043) and Days 14–28 ( P = 0.0079). The pronounced production of relevant antibodies and induction of cellular immunity is indicative of a mixed Th1/Th2 response and antibody‐dependent cellular cytotoxicity (ADCC) targeting O. volvulus L3 and/or other larval stages of the parasite.

Conclusion

These results position Ov MANE1 as a promising vaccine candidate against human onchocerciasis. However, further in vivo studies are needed to confirm and expand these findings.

Schlagwörter

Stichwörter der Autor:innen

BALB/c miceOvMANE1antibody and cellular immune responsechimeric antigenonchocerciasisvaccine

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Faculty of Science University of Buea Buea Cameroon.
  • Center for Drug Discovery University of Buea Buea Cameroon.
  • CoVACC, Community-Led Vaccination Yaoundé Cameroon.
  • Frailty in Ageing Research Group Vrije University Brussels Brussels Belgium.
  • Department of Gerontology, Faculty of Medicine and Pharmacy Vrije University Brussels Brussels Belgium.
  • Graduate School of Life Sciences Julius-Maximilians University WÜrzburg WÜrzburg Germany.

ORCID-Profile: Derrick Neba Nebangwa, Mary Teke Efeti, Robert Adamu Shey, Stephen Mbigha Ghogomu

Zitieren

APA

Nebangwa, D. N., Efeti, M. T., Momnougui, S. M. E., Shintouo, C. M., Shey, R. A., Ayiseh, R. B., Ntie-Kang, F., & Ghogomu, S. M. (2026). Safety and immunogenicity of an adjuvanted human onchocerciasis vaccine candidate, Ov MANE1 : preclinical evaluation in a mice model. Clinical & Translational Immunology, 15(7). https://doi.org/10.1002/cti2.70114

Vancouver

Nebangwa DN, Efeti MT, Momnougui SME, Shintouo CM, Shey RA, Ayiseh RB, et al. Safety and immunogenicity of an adjuvanted human onchocerciasis vaccine candidate, Ov MANE1 : preclinical evaluation in a mice model. Clinical & Translational Immunology. 2026;15(7). doi:10.1002/cti2.70114

BibTeX
@article{Nebangwa2026,
  author = {Nebangwa, Derrick Neba and Efeti, Mary Teke and Momnougui, Sonia M E and Shintouo, Cabirou Mounchili and Shey, Robert Adamu and Ayiseh, Rene Bilingwe and Ntie-Kang, Fidele and Ghogomu, Stephen Mbigha},
  title = {Safety and immunogenicity of an adjuvanted human onchocerciasis vaccine candidate, Ov MANE1 : preclinical evaluation in a mice model},
  journal = {Clinical & Translational Immunology},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/cti2.70114}
}
Kostenlos starten →